| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 43 | 2023 | 16718 | 1.750 |
Why?
|
| South Africa | 15 | 2023 | 1731 | 1.120 |
Why?
|
| CD4 Lymphocyte Count | 11 | 2020 | 2559 | 0.890 |
Why?
|
| Alendronate | 4 | 2005 | 171 | 0.740 |
Why?
|
| Beauty Culture | 1 | 2018 | 41 | 0.650 |
Why?
|
| Speech Disorders | 1 | 2018 | 189 | 0.590 |
Why?
|
| Anti-HIV Agents | 13 | 2020 | 4256 | 0.570 |
Why?
|
| Viral Load | 6 | 2020 | 3299 | 0.540 |
Why?
|
| Hair | 1 | 2018 | 483 | 0.510 |
Why?
|
| Contraception | 1 | 2018 | 359 | 0.500 |
Why?
|
| Constipation | 1 | 2018 | 546 | 0.460 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2005 | 275 | 0.440 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2019 | 810 | 0.420 |
Why?
|
| Patient Transfer | 1 | 2019 | 761 | 0.420 |
Why?
|
| Autistic Disorder | 4 | 2021 | 1185 | 0.380 |
Why?
|
| Lamivudine | 6 | 2017 | 342 | 0.380 |
Why?
|
| Medication Adherence | 3 | 2020 | 2063 | 0.360 |
Why?
|
| Hormone Replacement Therapy | 2 | 2005 | 745 | 0.350 |
Why?
|
| Osteoporosis, Postmenopausal | 4 | 2007 | 386 | 0.340 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 933 | 0.330 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2022 | 3923 | 0.330 |
Why?
|
| Anti-Retroviral Agents | 6 | 2022 | 1715 | 0.330 |
Why?
|
| Decision Support Techniques | 1 | 2017 | 1956 | 0.300 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2005 | 1203 | 0.300 |
Why?
|
| Refugees | 3 | 2020 | 511 | 0.270 |
Why?
|
| Tuberculosis | 1 | 2019 | 1912 | 0.270 |
Why?
|
| Models, Theoretical | 2 | 2017 | 3589 | 0.270 |
Why?
|
| Anxiety | 3 | 2023 | 4297 | 0.270 |
Why?
|
| Medroxyprogesterone | 1 | 2005 | 37 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 9 | 2018 | 5391 | 0.270 |
Why?
|
| Hip | 2 | 2017 | 257 | 0.270 |
Why?
|
| Reverse Transcriptase Inhibitors | 4 | 2017 | 615 | 0.250 |
Why?
|
| Bone Density | 6 | 2017 | 3468 | 0.250 |
Why?
|
| Adult | 51 | 2024 | 214055 | 0.240 |
Why?
|
| Female | 68 | 2023 | 380194 | 0.240 |
Why?
|
| Benzoxazines | 4 | 2017 | 301 | 0.240 |
Why?
|
| Progesterone Congeners | 1 | 2003 | 42 | 0.230 |
Why?
|
| Pancreatitis | 2 | 2013 | 1092 | 0.220 |
Why?
|
| Penicillins | 2 | 2016 | 380 | 0.220 |
Why?
|
| Humans | 89 | 2024 | 744343 | 0.220 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2003 | 162 | 0.210 |
Why?
|
| Trichomonas Infections | 1 | 2022 | 43 | 0.210 |
Why?
|
| Drug Monitoring | 2 | 2018 | 956 | 0.200 |
Why?
|
| HIV-1 | 8 | 2020 | 6939 | 0.200 |
Why?
|
| Stavudine | 5 | 2008 | 85 | 0.200 |
Why?
|
| Alkynes | 4 | 2017 | 306 | 0.200 |
Why?
|
| Bone Remodeling | 1 | 2005 | 575 | 0.190 |
Why?
|
| Cyclopropanes | 4 | 2017 | 416 | 0.190 |
Why?
|
| Male | 58 | 2023 | 350118 | 0.190 |
Why?
|
| Radiographic Image Enhancement | 3 | 2015 | 885 | 0.190 |
Why?
|
| Forecasting | 2 | 2020 | 2951 | 0.190 |
Why?
|
| Placebos | 3 | 2019 | 1676 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2006 | 2232 | 0.180 |
Why?
|
| Life Expectancy | 2 | 2016 | 1184 | 0.170 |
Why?
|
| Didanosine | 4 | 2007 | 153 | 0.170 |
Why?
|
| Models, Economic | 3 | 2018 | 713 | 0.170 |
Why?
|
| Pregnancy, Unwanted | 1 | 2018 | 26 | 0.170 |
Why?
|
| Bacteremia | 2 | 2016 | 962 | 0.170 |
Why?
|
| Nelfinavir | 3 | 2007 | 68 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2018 | 7913 | 0.160 |
Why?
|
| Motor Activity | 2 | 2005 | 2714 | 0.160 |
Why?
|
| Pica | 1 | 2018 | 32 | 0.160 |
Why?
|
| Chlamydia Infections | 1 | 2022 | 365 | 0.160 |
Why?
|
| Dental Care | 1 | 2020 | 262 | 0.160 |
Why?
|
| Family Characteristics | 1 | 2023 | 1000 | 0.160 |
Why?
|
| Gonorrhea | 1 | 2022 | 335 | 0.150 |
Why?
|
| Community Health Services | 2 | 2020 | 650 | 0.150 |
Why?
|
| Child Health Services | 2 | 2020 | 667 | 0.150 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 2716 | 0.150 |
Why?
|
| Psychomotor Performance | 1 | 2005 | 1901 | 0.150 |
Why?
|
| Diazoxide | 3 | 2007 | 57 | 0.150 |
Why?
|
| Drug Hypersensitivity | 2 | 2016 | 884 | 0.150 |
Why?
|
| Muscle Hypotonia | 1 | 2018 | 165 | 0.150 |
Why?
|
| Dideoxynucleosides | 1 | 2017 | 122 | 0.150 |
Why?
|
| Sputum | 1 | 2019 | 476 | 0.140 |
Why?
|
| Algorithms | 4 | 2019 | 13881 | 0.140 |
Why?
|
| Proportional Hazards Models | 3 | 2020 | 12354 | 0.140 |
Why?
|
| Cardioplegic Solutions | 2 | 2007 | 118 | 0.140 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 1400 | 0.140 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2018 | 304 | 0.140 |
Why?
|
| Treatment Failure | 2 | 2017 | 2618 | 0.140 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2022 | 624 | 0.140 |
Why?
|
| Eczema | 1 | 2018 | 231 | 0.130 |
Why?
|
| Absorptiometry, Photon | 4 | 2017 | 1725 | 0.130 |
Why?
|
| Cross-Sectional Studies | 7 | 2022 | 25043 | 0.130 |
Why?
|
| Probiotics | 1 | 2019 | 351 | 0.130 |
Why?
|
| Vitamin D Deficiency | 1 | 2005 | 1343 | 0.130 |
Why?
|
| Mass Screening | 4 | 2021 | 5255 | 0.130 |
Why?
|
| HIV | 4 | 2018 | 1604 | 0.130 |
Why?
|
| Public Sector | 1 | 2017 | 265 | 0.130 |
Why?
|
| Indinavir | 2 | 2005 | 74 | 0.130 |
Why?
|
| Employee Performance Appraisal | 1 | 2015 | 87 | 0.130 |
Why?
|
| Smoking Cessation | 2 | 2017 | 2071 | 0.130 |
Why?
|
| Educational Status | 1 | 2023 | 2540 | 0.130 |
Why?
|
| Financing, Personal | 1 | 2017 | 308 | 0.130 |
Why?
|
| Drug Substitution | 1 | 2017 | 281 | 0.130 |
Why?
|
| Random Allocation | 1 | 2019 | 2429 | 0.120 |
Why?
|
| Vitamin D | 2 | 2005 | 3223 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2022 | 738 | 0.120 |
Why?
|
| Income | 1 | 2023 | 1913 | 0.120 |
Why?
|
| Prevalence | 6 | 2022 | 15226 | 0.120 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 215 | 0.120 |
Why?
|
| Young Adult | 11 | 2023 | 56430 | 0.120 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2015 | 142 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2020 | 1147 | 0.120 |
Why?
|
| AIDS Serodiagnosis | 1 | 2014 | 184 | 0.120 |
Why?
|
| Social Support | 2 | 2020 | 2118 | 0.110 |
Why?
|
| Drug Combinations | 2 | 2017 | 1959 | 0.110 |
Why?
|
| Zidovudine | 4 | 2008 | 620 | 0.110 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2007 | 476 | 0.110 |
Why?
|
| Middle Aged | 32 | 2023 | 213383 | 0.110 |
Why?
|
| Feasibility Studies | 2 | 2024 | 5078 | 0.110 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2020 | 1873 | 0.110 |
Why?
|
| Heart Arrest | 1 | 2023 | 1470 | 0.110 |
Why?
|
| Lung Diseases | 1 | 2023 | 1886 | 0.110 |
Why?
|
| Double-Blind Method | 6 | 2007 | 12026 | 0.110 |
Why?
|
| Tomography, Spiral Computed | 1 | 2014 | 280 | 0.110 |
Why?
|
| Models, Statistical | 4 | 2019 | 5102 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2005 | 3297 | 0.110 |
Why?
|
| Indomethacin | 1 | 2013 | 332 | 0.110 |
Why?
|
| Internationality | 1 | 2018 | 1003 | 0.100 |
Why?
|
| Adolescent | 12 | 2023 | 85781 | 0.100 |
Why?
|
| Models, Educational | 1 | 2015 | 377 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 1411 | 0.100 |
Why?
|
| Anesthesia | 1 | 2023 | 1561 | 0.100 |
Why?
|
| Brain Concussion | 1 | 2023 | 1320 | 0.100 |
Why?
|
| United States | 14 | 2021 | 69872 | 0.100 |
Why?
|
| Research Design | 1 | 2007 | 5987 | 0.100 |
Why?
|
| Aging | 4 | 2020 | 8664 | 0.100 |
Why?
|
| Cohort Studies | 9 | 2022 | 40561 | 0.100 |
Why?
|
| Influenza, Human | 1 | 2022 | 1479 | 0.100 |
Why?
|
| Self Report | 2 | 2024 | 3558 | 0.100 |
Why?
|
| Drugs, Generic | 1 | 2015 | 421 | 0.090 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2013 | 197 | 0.090 |
Why?
|
| Computer Simulation | 3 | 2019 | 6196 | 0.090 |
Why?
|
| Health Care Costs | 3 | 2018 | 3209 | 0.090 |
Why?
|
| Research Support as Topic | 1 | 2015 | 705 | 0.090 |
Why?
|
| Smoking | 2 | 2017 | 8987 | 0.090 |
Why?
|
| Homosexuality, Male | 1 | 2018 | 1240 | 0.090 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2013 | 504 | 0.090 |
Why?
|
| Depression | 2 | 2021 | 7766 | 0.090 |
Why?
|
| Aged | 25 | 2020 | 163280 | 0.090 |
Why?
|
| Prospective Studies | 13 | 2023 | 53288 | 0.090 |
Why?
|
| Oxazines | 2 | 2015 | 298 | 0.090 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2014 | 1184 | 0.090 |
Why?
|
| Developmental Disabilities | 1 | 2018 | 1456 | 0.090 |
Why?
|
| Continuity of Patient Care | 1 | 2017 | 1049 | 0.090 |
Why?
|
| Primary Health Care | 3 | 2021 | 4558 | 0.090 |
Why?
|
| Body Composition | 3 | 2007 | 2401 | 0.090 |
Why?
|
| HIV Protease Inhibitors | 3 | 2008 | 430 | 0.080 |
Why?
|
| Drug Therapy, Combination | 5 | 2007 | 6489 | 0.080 |
Why?
|
| Contrast Media | 4 | 2015 | 5300 | 0.080 |
Why?
|
| Family | 1 | 2020 | 3147 | 0.080 |
Why?
|
| Infant | 3 | 2020 | 35136 | 0.080 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 1177 | 0.080 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2014 | 740 | 0.080 |
Why?
|
| Uganda | 3 | 2020 | 1243 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 3 | 2016 | 7181 | 0.080 |
Why?
|
| RNA, Viral | 1 | 2017 | 2902 | 0.080 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2015 | 687 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1504 | 0.080 |
Why?
|
| Staphylococcus aureus | 1 | 2016 | 1451 | 0.080 |
Why?
|
| Osteocalcin | 2 | 2007 | 273 | 0.080 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 2759 | 0.080 |
Why?
|
| Mortality | 1 | 2019 | 2864 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4386 | 0.080 |
Why?
|
| Geranyltranstransferase | 1 | 2007 | 5 | 0.080 |
Why?
|
| Trust | 2 | 2022 | 505 | 0.070 |
Why?
|
| Faculty, Medical | 1 | 2015 | 1181 | 0.070 |
Why?
|
| Time Factors | 11 | 2020 | 40075 | 0.070 |
Why?
|
| Child | 9 | 2021 | 77709 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2014 | 1180 | 0.070 |
Why?
|
| Research | 1 | 2015 | 1999 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2015 | 1161 | 0.070 |
Why?
|
| Health Services Accessibility | 2 | 2020 | 5137 | 0.070 |
Why?
|
| Testosterone | 2 | 2007 | 2420 | 0.070 |
Why?
|
| Isotonic Solutions | 1 | 2006 | 119 | 0.070 |
Why?
|
| Program Evaluation | 1 | 2015 | 2488 | 0.070 |
Why?
|
| Pregnancy | 4 | 2022 | 29144 | 0.070 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 5319 | 0.070 |
Why?
|
| Collagen Type I | 2 | 2007 | 592 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 7785 | 0.070 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 244 | 0.060 |
Why?
|
| Alkaline Phosphatase | 2 | 2007 | 865 | 0.060 |
Why?
|
| Densitometry | 1 | 2005 | 156 | 0.060 |
Why?
|
| Nucleosides | 1 | 2005 | 138 | 0.060 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2007 | 250 | 0.060 |
Why?
|
| Pediatrics | 1 | 2020 | 3475 | 0.060 |
Why?
|
| Abdominal Fat | 1 | 2006 | 223 | 0.060 |
Why?
|
| Canada | 2 | 2020 | 2065 | 0.060 |
Why?
|
| Bone and Bones | 2 | 2005 | 2575 | 0.060 |
Why?
|
| Lactates | 1 | 2005 | 432 | 0.060 |
Why?
|
| Hydroxyurea | 1 | 2005 | 290 | 0.060 |
Why?
|
| Comorbidity | 1 | 2018 | 10388 | 0.060 |
Why?
|
| Minerals | 1 | 2005 | 275 | 0.060 |
Why?
|
| Kidney Neoplasms | 2 | 2014 | 4262 | 0.060 |
Why?
|
| HN Protein | 1 | 2003 | 8 | 0.060 |
Why?
|
| Hyperinsulinism | 1 | 2007 | 415 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 476 | 0.060 |
Why?
|
| Femur Neck | 1 | 2005 | 309 | 0.060 |
Why?
|
| Interleukin-2 | 3 | 2005 | 1904 | 0.060 |
Why?
|
| Blood Specimen Collection | 1 | 2005 | 246 | 0.060 |
Why?
|
| Kidney | 3 | 2014 | 7186 | 0.060 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 4933 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2018 | 13102 | 0.060 |
Why?
|
| Macaca fascicularis | 1 | 2005 | 915 | 0.060 |
Why?
|
| Cholinergic Fibers | 1 | 2003 | 68 | 0.060 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 535 | 0.060 |
Why?
|
| Schools | 2 | 2023 | 1433 | 0.060 |
Why?
|
| Calcium | 2 | 2007 | 5756 | 0.060 |
Why?
|
| Melanoma | 3 | 2010 | 5510 | 0.060 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2018 | 3658 | 0.050 |
Why?
|
| Carotid Artery Thrombosis | 1 | 2002 | 53 | 0.050 |
Why?
|
| Telemedicine | 1 | 2020 | 2872 | 0.050 |
Why?
|
| Epilepsy | 1 | 2018 | 3310 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2024 | 9959 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2010 | 1708 | 0.050 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2003 | 82 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2020 | 41006 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2003 | 165 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2014 | 20129 | 0.050 |
Why?
|
| Aged, 80 and over | 9 | 2018 | 57776 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 780 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 1677 | 0.050 |
Why?
|
| Risk Factors | 11 | 2019 | 72290 | 0.050 |
Why?
|
| Albuminuria | 1 | 2005 | 682 | 0.050 |
Why?
|
| Mitochondria, Heart | 1 | 2002 | 247 | 0.050 |
Why?
|
| Postural Balance | 1 | 2005 | 620 | 0.050 |
Why?
|
| Colonic Diseases, Functional | 1 | 2000 | 38 | 0.050 |
Why?
|
| Prosencephalon | 1 | 2003 | 303 | 0.050 |
Why?
|
| Interleukin-13 | 1 | 2003 | 389 | 0.050 |
Why?
|
| Stents | 1 | 2013 | 3280 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2010 | 11524 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2005 | 1654 | 0.050 |
Why?
|
| Body Weight | 3 | 2006 | 4669 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2010 | 1938 | 0.050 |
Why?
|
| Oxygen Consumption | 1 | 2007 | 1869 | 0.050 |
Why?
|
| Diphosphonates | 1 | 2005 | 623 | 0.050 |
Why?
|
| Dehydroepiandrosterone | 1 | 2021 | 252 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2005 | 694 | 0.040 |
Why?
|
| Simian immunodeficiency virus | 1 | 2005 | 846 | 0.040 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2020 | 162 | 0.040 |
Why?
|
| Metformin | 1 | 2007 | 835 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2010 | 1972 | 0.040 |
Why?
|
| Stroke | 2 | 2018 | 9981 | 0.040 |
Why?
|
| Dacarbazine | 1 | 2002 | 566 | 0.040 |
Why?
|
| Pilot Projects | 4 | 2019 | 8324 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 2734 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 11725 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2022 | 724 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2005 | 3143 | 0.040 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2002 | 475 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2015 | 3309 | 0.040 |
Why?
|
| Hypertension | 1 | 2019 | 8480 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2005 | 2375 | 0.040 |
Why?
|
| Positive-Pressure Respiration | 1 | 2023 | 633 | 0.040 |
Why?
|
| Femur | 1 | 2005 | 1297 | 0.040 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2003 | 329 | 0.040 |
Why?
|
| Treatment Outcome | 10 | 2017 | 63114 | 0.040 |
Why?
|
| Observer Variation | 2 | 2015 | 2593 | 0.040 |
Why?
|
| Bone Density Conservation Agents | 1 | 2005 | 773 | 0.040 |
Why?
|
| Walking | 1 | 2005 | 1180 | 0.040 |
Why?
|
| Quality of Life | 1 | 2019 | 12804 | 0.040 |
Why?
|
| Case Management | 1 | 2020 | 286 | 0.040 |
Why?
|
| Estrogens | 1 | 2005 | 1566 | 0.040 |
Why?
|
| Mozambique | 1 | 2017 | 54 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2021 | 553 | 0.040 |
Why?
|
| Accidental Falls | 1 | 2005 | 1062 | 0.040 |
Why?
|
| Fentanyl | 1 | 2000 | 410 | 0.040 |
Why?
|
| Skin Neoplasms | 2 | 2010 | 5686 | 0.040 |
Why?
|
| Rural Population | 2 | 2018 | 2210 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2017 | 2886 | 0.040 |
Why?
|
| Universities | 1 | 2023 | 956 | 0.040 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 19905 | 0.040 |
Why?
|
| Adipose Tissue | 2 | 2006 | 3279 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2021 | 703 | 0.040 |
Why?
|
| North America | 1 | 2020 | 1249 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2000 | 584 | 0.040 |
Why?
|
| Methicillin | 1 | 2016 | 59 | 0.030 |
Why?
|
| Collagen | 1 | 2005 | 2689 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2020 | 397 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2005 | 2418 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 417 | 0.030 |
Why?
|
| Postmenopause | 1 | 2005 | 2461 | 0.030 |
Why?
|
| Boston | 2 | 2007 | 9313 | 0.030 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 4456 | 0.030 |
Why?
|
| Kenya | 1 | 2018 | 685 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2002 | 1261 | 0.030 |
Why?
|
| Sex Characteristics | 1 | 2006 | 2585 | 0.030 |
Why?
|
| Regression Analysis | 3 | 2016 | 6459 | 0.030 |
Why?
|
| Demography | 2 | 2015 | 1656 | 0.030 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 2 | 2007 | 138 | 0.030 |
Why?
|
| Myocardial Ischemia | 1 | 2006 | 2148 | 0.030 |
Why?
|
| Brachiocephalic Veins | 1 | 2015 | 23 | 0.030 |
Why?
|
| Subclavian Vein | 1 | 2015 | 54 | 0.030 |
Why?
|
| Forearm | 1 | 2017 | 409 | 0.030 |
Why?
|
| Voluntary Programs | 1 | 2014 | 42 | 0.030 |
Why?
|
| Attitude | 1 | 2020 | 776 | 0.030 |
Why?
|
| beta-Lactams | 1 | 2016 | 160 | 0.030 |
Why?
|
| Iopamidol | 1 | 2015 | 191 | 0.030 |
Why?
|
| Registries | 2 | 2020 | 8089 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2007 | 2872 | 0.030 |
Why?
|
| Skin Tests | 1 | 2016 | 613 | 0.030 |
Why?
|
| Blood Circulation | 1 | 2015 | 251 | 0.030 |
Why?
|
| Michigan | 1 | 2015 | 350 | 0.030 |
Why?
|
| Jugular Veins | 1 | 2015 | 204 | 0.030 |
Why?
|
| Mitochondria | 1 | 2007 | 3520 | 0.030 |
Why?
|
| Blood Glucose | 2 | 2005 | 6256 | 0.030 |
Why?
|
| Phlebography | 1 | 2015 | 333 | 0.030 |
Why?
|
| Tanzania | 1 | 2018 | 1346 | 0.030 |
Why?
|
| Obesity | 3 | 2021 | 12745 | 0.030 |
Why?
|
| Health Resources | 1 | 2020 | 911 | 0.030 |
Why?
|
| Administration, Rectal | 1 | 2013 | 73 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 2021 | 1826 | 0.030 |
Why?
|
| Biostatistics | 1 | 2015 | 162 | 0.030 |
Why?
|
| Clinical Competence | 2 | 2020 | 4687 | 0.030 |
Why?
|
| Budgets | 1 | 2015 | 229 | 0.030 |
Why?
|
| Vancomycin | 1 | 2016 | 501 | 0.030 |
Why?
|
| Sex Factors | 1 | 2007 | 10397 | 0.030 |
Why?
|
| Insulin Resistance | 2 | 2005 | 3864 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2018 | 738 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2004 | 3778 | 0.030 |
Why?
|
| Incidence | 2 | 2015 | 20947 | 0.030 |
Why?
|
| Writing | 1 | 2015 | 206 | 0.030 |
Why?
|
| Retrospective Studies | 7 | 2016 | 77449 | 0.030 |
Why?
|
| Peptides | 1 | 2005 | 4409 | 0.030 |
Why?
|
| Authorship | 1 | 2015 | 271 | 0.030 |
Why?
|
| Survivors | 1 | 2023 | 2291 | 0.030 |
Why?
|
| Age Factors | 2 | 2007 | 18370 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2020 | 2309 | 0.030 |
Why?
|
| Faculty | 1 | 2015 | 386 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 968 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 684 | 0.030 |
Why?
|
| Pandemics | 2 | 2022 | 8388 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 2014 | 486 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 1270 | 0.030 |
Why?
|
| Anxiety Disorders | 1 | 2023 | 2690 | 0.020 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 1683 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2016 | 1184 | 0.020 |
Why?
|
| Subtraction Technique | 1 | 2014 | 525 | 0.020 |
Why?
|
| Feedback | 1 | 2015 | 795 | 0.020 |
Why?
|
| Pyridones | 1 | 2015 | 712 | 0.020 |
Why?
|
| Lipids | 3 | 2007 | 3305 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2000 | 3420 | 0.020 |
Why?
|
| Spine | 1 | 2017 | 1144 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2016 | 1877 | 0.020 |
Why?
|
| Eosinophils | 1 | 2015 | 955 | 0.020 |
Why?
|
| Rabbits | 2 | 2007 | 4894 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3278 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2005 | 4445 | 0.020 |
Why?
|
| Urban Population | 1 | 2017 | 2021 | 0.020 |
Why?
|
| Risk | 2 | 2015 | 9687 | 0.020 |
Why?
|
| Pulmonary Veins | 1 | 2015 | 761 | 0.020 |
Why?
|
| Heart Atria | 1 | 2015 | 1357 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 3022 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2014 | 1915 | 0.020 |
Why?
|
| Cognition | 1 | 2005 | 6770 | 0.020 |
Why?
|
| Drug Costs | 1 | 2015 | 1105 | 0.020 |
Why?
|
| Allergens | 1 | 2015 | 1320 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2018 | 2925 | 0.020 |
Why?
|
| Teaching | 1 | 2015 | 1174 | 0.020 |
Why?
|
| Heart Ventricles | 2 | 2015 | 3821 | 0.020 |
Why?
|
| Health Personnel | 1 | 2021 | 3218 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2005 | 10180 | 0.020 |
Why?
|
| Lung | 2 | 2023 | 9856 | 0.020 |
Why?
|
| Triage | 1 | 2014 | 976 | 0.020 |
Why?
|
| Neoplasm Metastasis | 2 | 2010 | 4851 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2008 | 369 | 0.020 |
Why?
|
| Communication | 1 | 2020 | 3749 | 0.020 |
Why?
|
| Ritonavir | 1 | 2008 | 322 | 0.020 |
Why?
|
| Parents | 1 | 2020 | 3407 | 0.020 |
Why?
|
| Apoptosis | 1 | 2002 | 9727 | 0.020 |
Why?
|
| Pulmonary Artery | 1 | 2015 | 1912 | 0.020 |
Why?
|
| Artifacts | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2008 | 371 | 0.020 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 1164 | 0.020 |
Why?
|
| Myocardial Reperfusion | 1 | 2007 | 351 | 0.020 |
Why?
|
| Waist-Hip Ratio | 1 | 2007 | 517 | 0.020 |
Why?
|
| Neoplasms | 1 | 2014 | 21683 | 0.020 |
Why?
|
| Exercise | 1 | 2021 | 5615 | 0.020 |
Why?
|
| Caregivers | 1 | 2017 | 2094 | 0.020 |
Why?
|
| Piperazines | 1 | 2015 | 2488 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2004 | 6487 | 0.020 |
Why?
|
| Sodium Fluoride | 1 | 2005 | 65 | 0.020 |
Why?
|
| Oxalates | 1 | 2005 | 105 | 0.020 |
Why?
|
| Analgesics, Opioid | 1 | 2000 | 3674 | 0.010 |
Why?
|
| Blood Preservation | 1 | 2005 | 177 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2015 | 2708 | 0.010 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2005 | 221 | 0.010 |
Why?
|
| Magnesium | 1 | 2007 | 813 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2016 | 10252 | 0.010 |
Why?
|
| Diet | 1 | 2021 | 7939 | 0.010 |
Why?
|
| Acidosis, Lactic | 1 | 2005 | 142 | 0.010 |
Why?
|
| Potassium Channels | 1 | 2006 | 563 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2019 | 8554 | 0.010 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2003 | 65 | 0.010 |
Why?
|
| Body Size | 1 | 2006 | 461 | 0.010 |
Why?
|
| Hospitals | 1 | 2017 | 3952 | 0.010 |
Why?
|
| Adenine | 1 | 2008 | 936 | 0.010 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2003 | 32 | 0.010 |
Why?
|
| Potassium | 1 | 2007 | 1336 | 0.010 |
Why?
|
| Vaccines, Inactivated | 1 | 2003 | 184 | 0.010 |
Why?
|
| Viremia | 1 | 2005 | 736 | 0.010 |
Why?
|
| Cytokines | 2 | 2010 | 7322 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2003 | 666 | 0.010 |
Why?
|
| Perfusion | 1 | 2006 | 1360 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2002 | 643 | 0.010 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2002 | 295 | 0.010 |
Why?
|
| Formaldehyde | 1 | 2003 | 353 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2002 | 8863 | 0.010 |
Why?
|
| Vaccinia virus | 1 | 2003 | 349 | 0.010 |
Why?
|
| Cerebral Infarction | 1 | 2006 | 1011 | 0.010 |
Why?
|
| Vinblastine | 1 | 2002 | 502 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2003 | 892 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2003 | 758 | 0.010 |
Why?
|
| Species Specificity | 1 | 2005 | 2478 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2003 | 579 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 440 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2006 | 1375 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2003 | 1095 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 1539 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2023 | 15295 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2007 | 2025 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 11366 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 5751 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 758 | 0.010 |
Why?
|
| Insulin | 2 | 2006 | 6580 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 1420 | 0.010 |
Why?
|
| Creatinine | 1 | 2005 | 1919 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 2003 | 1150 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2002 | 648 | 0.010 |
Why?
|
| Caspases | 1 | 2002 | 928 | 0.010 |
Why?
|
| Receptors, Opioid, mu | 1 | 2000 | 182 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 2003 | 1147 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 2006 | 1782 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2003 | 635 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 2645 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39050 | 0.010 |
Why?
|
| Models, Biological | 1 | 2015 | 9583 | 0.010 |
Why?
|
| HIV Antibodies | 1 | 2005 | 1322 | 0.010 |
Why?
|
| Immunization | 1 | 2003 | 1256 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2002 | 895 | 0.010 |
Why?
|
| Dyslipidemias | 1 | 2005 | 849 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 14722 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 12959 | 0.010 |
Why?
|
| Family Health | 1 | 2003 | 1282 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2003 | 1061 | 0.010 |
Why?
|
| Disease Progression | 1 | 2014 | 13284 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2002 | 1066 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2002 | 2274 | 0.010 |
Why?
|
| Cisplatin | 1 | 2002 | 1662 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2016 | 25625 | 0.010 |
Why?
|
| Animals | 5 | 2007 | 168757 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 1434 | 0.010 |
Why?
|
| Rectum | 1 | 2000 | 904 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2003 | 6386 | 0.010 |
Why?
|
| Ventricular Function, Left | 1 | 2006 | 3670 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 6622 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 5917 | 0.010 |
Why?
|
| Genotype | 1 | 2007 | 12951 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2002 | 6895 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2003 | 3176 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2000 | 6365 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 13989 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 4554 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2005 | 16689 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 15997 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 12788 | 0.000 |
Why?
|
| Mice, Knockout | 1 | 2003 | 14557 | 0.000 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2007 | 15519 | 0.000 |
Why?
|
| Prognosis | 1 | 2005 | 29063 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 2002 | 15540 | 0.000 |
Why?
|
| Inflammation | 1 | 2003 | 10638 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2000 | 21746 | 0.000 |
Why?
|
| Alzheimer Disease | 1 | 2003 | 8037 | 0.000 |
Why?
|
| Cardiovascular Diseases | 1 | 2005 | 15165 | 0.000 |
Why?
|
| Mice | 1 | 2003 | 81183 | 0.000 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2002 | 35421 | 0.000 |
Why?
|